Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)Matthias Preusser, Wolfgang Wick, Giuseppe Lombardi et al.|Neuro-Oncology|2021Cited by 81
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerPierre-Étienne Heudel, Jean-Luc Soubirou, Sylvie Chabaud et al.|ESMO Open|2021Cited by 35